Biosyn Arzneimittel Gmbh

Other

Biosyn Arzeimittel Gmbh

Thomas Stiefel

Jürgen Markl

Benjamin Altenhein

Bernhard Lieb

Ortwin Kottwitz

Peter Welters

Peter Morris

Wolfgang Voelter

Shammana N Muddukrishna

Helmut R&ouml;hrer

Jurgen Markl

Harald Porcher

Bernard Lieb

The present invention relates to the provision of a biologically safe hemolymph sera, preferably hemocyanin, more preferably KLH (keyhole limpet hemocyanin). The hemocyanin is purified using anion exchange chromatography.

Preparation methods for a novel generation of biological safe KLH products used for cancer treatment, for the development of conjugated therapeutic vaccines and as challenging agents

The present invention relates to the provision of a biologically safe hemolymph sera, preferably hemocyanin, more preferably KLH (keyhole limpet hemocyanin). A method for producing virus free hemocyanin is provided.

The present invention relates to a composition with trace elements for nutrition. The composition is characterized by an increased content of selenium and/or zinc as a trace element.

Nutrition trace element composition

The present invention relates to means and methods for producing crystals or crystalline substances. In particular, crystals or crystalline substances which are useful as pharmaceutical ingredients can be manufactured.

Method of producing pharmacologically pure crystals

A nucleic acid molecule or construct alone or with a promoter suitable for expression control is contemplated that codes for a KLH1 haemocyanin, a haemocyanin domain or a fragment thereof with the immunological properties of at least one domain of haemocyanin, and comprises at least one intron sequence, as well as haemocyanin fusion proteins. The construct can also comprise a nucleic acid sequence that codes for an antigen. Host cells are also contemplated that contain the nucleic acid molecule or construct and a recombinant expression product thereof. The invention further relates to a pharmaceutical composition that comprises the expression product and antibodies obtainable by immunization of an animal therewith, as well as the use of antibodies in screening methods for the identification of tumors.

Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin

A nucleic acid molecule or construct alone or with a promoter suitable for expression control is contemplated that codes for a HLH2 haemocyanin polypeptide and comprises at least one intron sequence, as well as haemocyanin fusion proteins. The construct further can comprise a nucleic acid sequence that codes for an antigen. Host cells are also contemplated that contain the nucleic acid molecules or construct and recombinant expression product thereof. The invention further relates to a pharmaceutical composition that comprises the expression product of that nucleic acid and antibodies obtainable by immunization of an animal therewith, as well as use of the antibodies in screening methods for the identification of tumors.

Nucleic acid molecule comprising a nucleic acid sequence coding for a haemocyanin

The present invention relates to processes for the production of mistletoe lectin polypeptides in homologous and heterologous host systems and mistletoe lectin peptides. Further, nucleic acid molecules are provided, which encode these mistletoe lectin polypeptides, and also pharmaceutical compositions comprising mistletoe lectin nucleic acids. The present invention also relates to isolated mistletoe lectin polypeptides and pharmaceutical compositions comprising said polypeptides.

Recombinant mistletoe lectin

A nucleic acid molecule or construct alone or with a promoter suitable for expression control is contemplated that codes for a haemocyanin, a haemocyanin domain or a fragment thereof with the immunological properties of at least one domain of haemocyanin, and comprises at least one intron sequence, as well as haemocyanin fusion proteins. The construct furthermore can comprise a nucleic acid sequence that codes for an antigen. Host cells are also contemplated that contain the nucleic acid molecule or construct and a recombinant expression product thereof. The invention furthermore relates to a pharmaceutical composition that comprises the expression product and antibodies obtainable by immunization of an animal therewith, as well as the use the antibodies in screening methods for the identification of tumors.

Nucleic acid molecule comprising a nucleic acid sequence which codes for a haemocyanin, and comprising at least one intron sequence

The present invention relates to isolated mistletoe lectin polypeptides and the pharmaceutical composition comprising the polypeptides thereof. Also, the present invention relates to processes for the production of mistletoe lectin polypeptides in homologous and heterologous host systems and mistletoe lectin peptides. Further, nucleic acid molecules are provided, which encode these mistletoe lectin polypeptides, and also pharmaceutical compositions comprising mistletoe lectin nucleic acids.

Recombinant mistletoe lectines

Combination of selenium-containing compounds with cytostatics

The invention deals with the use of hemocyanin, other than keyhole-limpet hemocyanin, arylphorin, or a combination thereof to influence the immune system and for the treatment of tumors.

Growing community of inventors

Stuttgart, Germany

Thomas Stiefel